Matches in SemOpenAlex for { <https://semopenalex.org/work/W2903823218> ?p ?o ?g. }
- W2903823218 endingPage "12" @default.
- W2903823218 startingPage "1" @default.
- W2903823218 abstract "Neuroblastoma (NB) is a pediatric cancer of the sympathetic nervous system which accounts for 8% of childhood cancers. Most NBs express high levels of the disialoganglioside GD2. Several antibodies have been developed to target GD2 on NB, including the human/mouse chimeric antibody ch14.18, known as dinutuximab. Dinutuximab used in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2, and isotretinoin (13-cis-retinoic acid) has a US Food and Drug Administration (FDA)-registered indication for treating high-risk NB patients who achieved at least a partial response to prior first-line multi-agent, multimodality therapy. The FDA registration resulted from a prospective randomized trial assessing the benefit of adding dinutuximab + cytokines to post-myeloablative maintenance therapy for high-risk NB. Dinutuximab has also shown promising antitumor activity when combined with temozolomide and irinotecan in treating NB progressive disease. Clinical activity of dinutuximab and other GD2-targeted therapies relies on the presence of the GD2 antigen on NB cells. Some NBs have been reported as GD2 low or negative, and such tumor cells could be nonresponsive to anti-GD2 therapy. As dinutuximab relies on complement and effector cells to mediate NB killing, factors affecting those components of patient response may also decrease dinutuximab effectiveness. This review summarizes the development of GD2 antibody-targeted therapy, the use of dinutuximab in both up-front and salvage therapy for high-risk NB, and the potential mechanisms of resistance to dinutuximab." @default.
- W2903823218 created "2018-12-22" @default.
- W2903823218 creator A5030014016 @default.
- W2903823218 creator A5034353350 @default.
- W2903823218 date "2018-12-01" @default.
- W2903823218 modified "2023-10-14" @default.
- W2903823218 title "Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy" @default.
- W2903823218 cites W1482959489 @default.
- W2903823218 cites W1496047440 @default.
- W2903823218 cites W1509521528 @default.
- W2903823218 cites W1562430079 @default.
- W2903823218 cites W1575002436 @default.
- W2903823218 cites W1605211533 @default.
- W2903823218 cites W1901831739 @default.
- W2903823218 cites W1915556294 @default.
- W2903823218 cites W1951179504 @default.
- W2903823218 cites W1957303411 @default.
- W2903823218 cites W1960710326 @default.
- W2903823218 cites W1967769371 @default.
- W2903823218 cites W1969208169 @default.
- W2903823218 cites W1972782437 @default.
- W2903823218 cites W1973699352 @default.
- W2903823218 cites W1986399662 @default.
- W2903823218 cites W1991861013 @default.
- W2903823218 cites W1992578082 @default.
- W2903823218 cites W1993940563 @default.
- W2903823218 cites W2003989093 @default.
- W2903823218 cites W2007527741 @default.
- W2903823218 cites W2015155629 @default.
- W2903823218 cites W2015858520 @default.
- W2903823218 cites W2017515622 @default.
- W2903823218 cites W2021673773 @default.
- W2903823218 cites W2024788439 @default.
- W2903823218 cites W2030700706 @default.
- W2903823218 cites W2034015697 @default.
- W2903823218 cites W2034018980 @default.
- W2903823218 cites W2036031859 @default.
- W2903823218 cites W2036406204 @default.
- W2903823218 cites W2037313669 @default.
- W2903823218 cites W2039226259 @default.
- W2903823218 cites W2039759999 @default.
- W2903823218 cites W2050935839 @default.
- W2903823218 cites W2052243796 @default.
- W2903823218 cites W2052955579 @default.
- W2903823218 cites W2056849373 @default.
- W2903823218 cites W2061770965 @default.
- W2903823218 cites W2064013031 @default.
- W2903823218 cites W2064510700 @default.
- W2903823218 cites W2066925870 @default.
- W2903823218 cites W2067216204 @default.
- W2903823218 cites W2067431214 @default.
- W2903823218 cites W2067590368 @default.
- W2903823218 cites W2068512864 @default.
- W2903823218 cites W2070369806 @default.
- W2903823218 cites W2081513802 @default.
- W2903823218 cites W2095296988 @default.
- W2903823218 cites W2102118318 @default.
- W2903823218 cites W2102140366 @default.
- W2903823218 cites W2102739282 @default.
- W2903823218 cites W2106545303 @default.
- W2903823218 cites W2108399323 @default.
- W2903823218 cites W2108555563 @default.
- W2903823218 cites W2120089299 @default.
- W2903823218 cites W2121146521 @default.
- W2903823218 cites W2125123324 @default.
- W2903823218 cites W2126292183 @default.
- W2903823218 cites W2129702476 @default.
- W2903823218 cites W2130465135 @default.
- W2903823218 cites W2130926603 @default.
- W2903823218 cites W2136462971 @default.
- W2903823218 cites W2138983295 @default.
- W2903823218 cites W2138985980 @default.
- W2903823218 cites W2143252790 @default.
- W2903823218 cites W2143634092 @default.
- W2903823218 cites W2144436556 @default.
- W2903823218 cites W2145985838 @default.
- W2903823218 cites W2147800896 @default.
- W2903823218 cites W2149820534 @default.
- W2903823218 cites W2151310238 @default.
- W2903823218 cites W2155614959 @default.
- W2903823218 cites W2157446638 @default.
- W2903823218 cites W2158514490 @default.
- W2903823218 cites W2160600470 @default.
- W2903823218 cites W2161798205 @default.
- W2903823218 cites W2164073959 @default.
- W2903823218 cites W2167550136 @default.
- W2903823218 cites W2171445183 @default.
- W2903823218 cites W2179454156 @default.
- W2903823218 cites W2271663961 @default.
- W2903823218 cites W2280912529 @default.
- W2903823218 cites W2327522594 @default.
- W2903823218 cites W2330978427 @default.
- W2903823218 cites W2331868380 @default.
- W2903823218 cites W2407062242 @default.
- W2903823218 cites W2409426515 @default.
- W2903823218 cites W2487956862 @default.
- W2903823218 cites W2506905645 @default.
- W2903823218 cites W2524515200 @default.